Ionis Pharmaceuticals NASDAQ: IONS is working to accelerate prescriptions for TRYNGOLZA as physicians gain experience with the drug and patients navigate insurance requirements, CEO Brett Monia said at the Jefferies Global Healthcare Conference.
NEW YORK, Nov. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference showed slowing of clinical decline across measures.
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA⢠(olezarsen) as an adjunct to
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). TRYNGOLZA is the first and only RNA-targeted therapy authorized in the EU for adults with sHTG ≥880 mg/dL (≥10 mmol/L). The app.
Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference.
Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Nov. 16, 2026 TRYNGOLZA sales fell to $9.3 million fro
TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholders who lost money.